Abstract
Objectives To explore effective prevention and control measures for Coronavirus Disease 2019 (COVID-19) in large international events through simulations of different interventions according to risk assessment.
Methods We used random model to calculate the number of initial infected patients. And Poisson distribution was used to determine the number of initial infected patients based on the number of countries involved. Further, to simulate the COVID-19 transmission, the susceptible-exposed-symptomatic-asymptomatic-recovered-hospitalized (SEIARH) model was established based on susceptible-exposed-infectious-recovered (SEIR) mathematical model of epidemic diseases. According to risk assessment indicators produced by different scenarios of the simulated interventions, the risk of COVID-19 transmission in Tokyo Olympic Games was assessed.
Results The large-scale vaccination will effectively control the spread of COVID-19. If the effective rate of vaccine is 100%, and the vaccination rate of athletes reaches 80%, an epidemic prevention barrier can be established.
Conclusions The current COVID-19 prevention measures proposed by the Japan Olympic Committee were needed to be enhanced. For the vaccination intervention had the best control effect, a mass vaccination serves was an effective way to control COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research work was funded by Sichuan Science and Technology Program (grant numbers 2020YFS0015, 2020YFS0091), Health Commission of Sichuan province (20PJ092), National Natural Science Foundation of China (grant numbers 81602935), Chongqing Science and Technology Program (grant numbers cstc2020jscxcylhX0003), Sichuan University (grant numbers 2018hhf-26, GSSCU2018038) and Liang Shan Zhou Center for Disease Control and Prevention. The funders played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The survey was discussed with the Ethics Committee of West China fourth Hospital, West China School of Public Health, Sichuan University, who reviewed the content. And the ethical approval was waived.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.